U.S. markets close in 2 hours 36 minutes
  • S&P 500

    3,861.08
    -9.21 (-0.24%)
     
  • Dow 30

    31,542.96
    +151.44 (+0.48%)
     
  • Nasdaq

    13,190.20
    -168.59 (-1.26%)
     
  • Russell 2000

    2,239.10
    +7.59 (+0.34%)
     
  • Crude Oil

    61.82
    +2.07 (+3.46%)
     
  • Gold

    1,716.40
    -17.20 (-0.99%)
     
  • Silver

    26.38
    -0.50 (-1.86%)
     
  • EUR/USD

    1.2080
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • GBP/USD

    1.3974
    +0.0018 (+0.13%)
     
  • USD/JPY

    106.9260
    +0.2160 (+0.20%)
     
  • BTC-USD

    51,554.59
    +3,865.14 (+8.10%)
     
  • CMC Crypto 200

    1,032.30
    +44.20 (+4.47%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Neurocrine Biosciences to Participate at the William Blair Biotech Focus Conference 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Live Webcast will be on August 6, 2020

SAN DIEGO, July 30, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the William Blair Biotech Focus Conference 2020 at 12:00 p.m. ET on Thursday, August 6, 2020. Kyle Gano, Chief Business Development and Strategy Officer, will participate in a panel session titled "New Therapies Impacting the Epilepsy Treatment Landscape" at the conference.

(PRNewsfoto/Neurocrine Biosciences, Inc.)
(PRNewsfoto/Neurocrine Biosciences, Inc.)

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, with three pivotal and five mid-stage clinical development programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-the-william-blair-biotech-focus-conference-2020-301103412.html

SOURCE Neurocrine Biosciences, Inc.